IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 42.654
Totale 42.654
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 42.654
Totale 42.654
Salva come PNG Salva come JPEG
Città #
Genova 32.783
Rapallo 4.071
Genoa 3.161
Vado Ligure 2.574
Bordighera 65
Totale 42.654
Salva come PNG Salva come JPEG
Nome #
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 244
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 189
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 187
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 168
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 163
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 161
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 160
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 160
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 154
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 154
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 153
Differentiating PFAPA syndrome from monogenic periodic fevers. 152
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 151
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 150

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 148
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 148
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 146
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 145
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 144
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 144
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 141
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 135
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 135
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 135
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 134
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis 134
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 134
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 134
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 134
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 133
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 133
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 133
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 133
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 133
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 132
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 132
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 132
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 132
The role of imaging in juvenile idiopathic arthritis 132
Antiphospholipid antibody syndrome in pediatric patients. 131
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 131
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 131
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 131
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 131
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 130
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 129
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 129
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 129
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 128
Paediatric-onset systemic lupus erythematosus. 128
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 128
Recurrent pericarditis in Myhre syndrome. 127
Adapted versions of the Sharp-van Der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis 126
Tolerance and auto-immunity: 50 years after burnet. 125
Clinical assessment in juvenile dermatomyositis. 125
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 125
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 125
Diagnostic potential of hepcidin testing in pediatrics. 125
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 125
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 125
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 125
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 124
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 124
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 124
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 123
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 123
Level of agreement between children, parents and physicians in rating pain intensity in juvenile idiopathic arthritis. 122
Discordance between physician’s and parent’s global assessments in juvenile idiopathic arthritis 122
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 122
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 122
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman 121
Evaluation of response to methotrexate by a functional index in juvenile chronic arthritis. 121
Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. 121
Advances from clinical trials in juvenile idiopathic arthritis. 121
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 121
Advances in biomarkers for paediatric rheumatic diseases 121
Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. 121
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease 120
Chronic recurrent multifocal osteomyelitis with unusual features. 120
Preliminary definition of improvement in juvenile arthritis. 120
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 120
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 119
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 119
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 119
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. 119
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 119
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 119
Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. 118
Lupus nephritis in children. 118
Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis 117
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 117
Macrophage activation syndrome 117
Cytokines in juvenile rheumatoid arthritis. 117
The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. 117
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 117
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 117
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 116
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. 116
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 116
Totale 13.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.549
article - articoli 127.085
book - libri 0
conference - conferenze 194
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.270
Totale 257.098
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208.005 0 0 0 0 0 0 2.334 819 1.040 2.079 1.285 448
2020/20213.166 165 303 272 393 166 284 140 274 298 364 221 286
2021/20225.604 170 429 624 450 323 240 438 1.288 206 453 330 653
2022/20234.943 550 245 44 420 847 973 23 467 916 33 347 78
2023/20242.128 147 373 45 211 197 346 117 133 96 53 105 305
2024/20252.805 98 574 248 385 819 677 4 0 0 0 0 0
Totale 43.226